NEW YORK (GenomeWeb News) – Quest Diagnostics today reported a 3 percent drop in third-quarter revenues, missing consensus Wall Street estimates.

For the quarter ended Sept. 30, the company posted $1.85 billion in revenues, down from $1.91 billion a year ago, and short of the average Wall Street estimate of $1.91 billion.

Clinical testing revenues dropped by 2 percent year over year, with volume, measured by the number of requisitions, down about 1 percent, and revenue per requisition also down 1 percent, Quest said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.